Pyrrole Derivative Potassium-Competitive Acid Blocker
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing proton pump inhibitors are unstable under acidic conditions, exhibit inconsistent treatment effects due to metabolic enzyme polymorphism and drug interactions, and require extended time for maximum efficacy, limiting their effectiveness in treating peptic ulcers and reflux esophagitis.
Innovation Solution
A compound represented by the formula (Ia), which is a phenyl, furyl, or pyridyl group-based pyrrole derivative with specific substituents, acts as a potassium-competitive acid blocker, reversibly inhibiting the proton pump (H+/K+ -ATPase) and suppressing acid secretion, thereby providing a rapid and sustained therapeutic effect.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If existing proton pump inhibitors are used, then gastric acid secretion is suppressed, but they are unstable under acidic conditions requiring enteric preparation formulation
Solution Approach 1:
The patent applies parameter changes by modifying the chemical structure of the pyrrole compound through specific substituents (R1a, R2a, R3a, R4a, R5a) to enhance stability under acidic conditions. The compound formula (Ia) with defined structural parameters achieves stable acid secretion suppression without requiring enteric coating, directly resolving the contradiction between stability and formulation complexity
Solution Approach 2:
The invention extracts and eliminates the need for enteric preparation formulation by developing a pyrrole compound that is inherently stable in acidic environments. By removing the protective coating requirement, the patent simplifies the drug delivery system while maintaining effective acid suppression
2Speed
If existing proton pump inhibitors are administered, then acid secretion is inhibited, but several hours are required before effect expression and about 5 days for maximum efficacy
Solution Approach 1:
The pyrrole compound (Ia) is designed to be pre-active and stable in the stomach's acidic environment, eliminating the need for activation after ingestion. This preliminary preparation of the drug molecule enables immediate action upon contact with the proton pump, achieving rapid symptom relief within minutes rather than hours or days
Solution Approach 2:
The invention skips the prolonged activation and accumulation phase required by conventional proton pump inhibitors. The compound directly inhibits the H+/K+-ATPase enzyme upon reaching the stomach, rushing through the delayed onset period and achieving therapeutic effect within minutes
3Reliability
If existing proton pump inhibitors are used, then treatment effect is achieved, but inconsistent effects occur due to metabolic enzyme polymorphism and drug interaction
Solution Approach 1:
The pyrrole compound (Ia) acts as a selective intermediary that directly targets the H+/K+-ATPase enzyme without significant metabolism by cytochrome P450 enzymes. This direct action mechanism bypasses the metabolic pathways that cause polymorphism-related variability and drug interactions, ensuring consistent therapeutic effects across different patients and concurrent medications
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The compound (Ia) demonstrates a superior proton pump inhibitory effect, is stable under acidic conditions, shows minimal metabolic polymorphism influence, and has low cytotoxicity, allowing for rapid symptom alleviation and extended action without the need for enteric coating, making it suitable for treating various gastrointestinal disorders.
Implementation Method 1
acts as a potassium-competitive acid blocker, reversibly inhibiting the proton pump (H+/K+ -ATPase) and suppressing acid secretion
Data Source
AI summary
The present invention provides a compound having a superior acid secretion inhibitory effect and showing an antiulcer activity, which is represented by the formula (I) wherein R1 is an optionally substituted cyclic group, R2 is a substituent, R3 is an optionally substituted alkyl group, an acyl group, an optionally substituted hydroxy group, an optionally substituted amino group, a halogen atom, a cyano group or a nitro group, R4 and R5 are each a hydrogen atom, an optionally substituted alkyl group, an acyl group, an optionally substituted hydroxy group, an optionally substituted amino group, a halogen atom, a cyano group or a nitro group, R6 and R6' are each a hydrogen atom or an alkyl group, and n is an integer of 0 - 3, or a salt thereof.